Apart from the definition of the cumulative reward Y, domain evidence has shown that HbA1c is widely recognized and adopted as one of the most important health biomarkers for tailoring treatments for T2D patients [42], and studies have also revealed that overweight status affects the response to insulin‐involved therapy in T2D patients [43]. The gene discussed is INS; the disease is type 2 diabetes mellitus.